Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis has become an important therapeutic strategy for cancer treatment but, like other current targeted therapies, benefits experienced for late‐stage cancers can be curtailed by inherent refractoriness or by acquired drug resistance, requiring a need for better mechanistic understanding of such effects. Numerous preclinical studies have demonstrated that VEGF pathway inhibitors suppress primary tumour growth and metastasis. However, it has been recently reported that short‐term VEGF and VEGFR inhibition can paradoxically accelerate tumour invasiveness and metastasis in certain models. Here we comprehensively compare the effects of both antibody and small molecule receptor tyrosine kinase (RTK) inhibitors targeting the VEGF–VEGFR pathway, using short‐term therapy in various mouse models of metastasis. Our findings demonstrate that antibody inhibition of VEGF pathway molecules does not promote metastasis, in contrast to selected small molecule RTK inhibitors at elevated‐therapeutic drug dosages. In particular, a multi‐targeted RTK inhibitor, sunitinib, which most profoundly potentiated metastasis, also increased lung vascular permeability and promoted tumour cell extravasation. Mechanistically, sunitinib, but not anti‐VEGF treatment, attenuated endothelial barrier function in culture and caused a global inhibition of protein tyrosine phosphorylation, including molecules important for maintaining endothelial cell–cell junctions. Together these findings indicate that, rather than a specific consequence of inhibiting the VEGF signalling pathway, pharmacological inhibitors of the VEGF pathway can have dose‐ and drug class‐dependent side‐effects on the host vasculature. These findings also advocate for the continued identification of mechanisms of resistance to anti‐angiogenics and for therapy development to overcome it. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · cited 2×
“Subsequent FDA-approved cancer therapies targeting the VEGF–VEGFR pathway include five small molecule receptor tyrosine kinase (RTK) inhibitors, sunitinib (Sutent ), sorafenib (Nexavar ), pazopanib (Votrient ), vandetanib (Caprelsa ) and axitinib (Inlyta ) [2].”
BackgroundKowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
Self-citationCooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“…populations of 612 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. immune cells (e.g., Gr-1+ myeloid cells and Th17 cells) or pericyte coverage, which promote resistance through direct support of paracrine interactions with the endothelial cells (Carmeliet and Jain, 2011; Chung et al., 2013).”
InfluentialTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Self-citationAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Metadata
- Authors
- Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Komuves, L., Peale, F., & Ferrara, N.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2012-07-03
- Volume
- 227
- Issue
- 4
- Pages
- 404-416
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2011765548
- Cited by
- 87
- References
- 7
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors. https://app.cochat.ai/papers/10.1002/path.4052
- The paper
- Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Komuves, L., Peale, F., & Ferrara, N. (2012). Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of Pathology. https://doi.org/10.1002/path.4052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.